Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00368264
Other study ID # TRIAL V
Secondary ID Eudract-Nr. 2005
Status Terminated
Phase Phase 2/Phase 3
First received August 23, 2006
Last updated October 2, 2009
Start date September 2006
Est. completion date June 2009

Study information

Verified date October 2009
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority Austria: Federal Ministry for Health and Women
Study type Interventional

Clinical Trial Summary

Background:

Standard therapy is ill-defined for patients with systemic lupus erythematosus (SLE) suffering from the membraneous form of Lupus nephritis (WHO class V). Therapeutic options used at present include azathioprine.

In a small, open label safety study, patients with lupus nephritis, including patients with membraneous lupus nephritis, have experienced a long-lasting therapeutic response, with sustained reduction in proteinuria, following a 10 weeks course of 4 infusions of infliximab in combination with azathioprine. This short course appeared safe with regard to SLE activity, despite increases in autoantibody levels.

Study hypothesis:

1. The combination of four infusions of infliximab (5 mg/kg of body weight)administered at weeks 0, 2,6, and 10, with azathioprine will be faster than azathioprine alone in reducing proteinuria to less than 1.5 g/day in patients with active lupus nephritis WHO class V (proteinuria > 3g/day).

2. This combination therapy will show a tolerable safety profile with regard to SLE activity and infections.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date June 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- SLE (ACR criteria fulfilled) with biopsy-proven membranous glomerulonephritis (WHO class V).

- Proteinuria > 3 g/day despite adequate therapy with ACE inhibitors and steroids (at least 2 months treatment with steroids with a dose at any time of at least 50 mg prednisolone (or equivalent), and ACE inhibitors and/or AT II antagonists at their maximum daily dose or, if this cannot be reached, the maximum daily dose tolerated).

- Capacity to understand and sign an informed consent form.

- Men and women of childbearing potential must use adequate birth control measures for the duration of the study and should continue such precautions for 6 months after receiving the last infusion.

- No history of latent or active TB prior to screening.

- No signs or symptoms suggestive of active TB upon medical history and/or physical examination.

- No recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study agent.

- Within 1 month prior to the first administration of study agent, either have a negative tuberculin skin test, or have a newly identified positive tuberculin skin test during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study agent.

- Have a chest radiograph (both posterior-anterior and lateral views) with no evidence of current active TB or old inactive TB.

- Screening laboratory test results meet the following criteria:

- WBC (white blood cell count): > 3.0 109/L

- Hemoglobin: > 6 mmol/L (9,6 g/dL)

- Platelets: 100-350 109/L

- Serum Creatinine: 1.5 times the upper limit of normal range

- ALAT / ASAT within twice the upper normal range.

Exclusion Criteria:

- Active WHO class IV SLE nephritis.

- Treatment with Azathioprine within the previous 12 months.

- Treatment with cyclophosphamide within the previous 12 months.

- Treatment with cyclosporine within the previous 6 weeks.

- Active cerebral SLE

- Presence of anti-phospholipid-antibodies unless under adequate anticoagulation

- Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion.

- Have had any previous treatment with monoclonal antibodies or antibody fragments.

- History of receiving human/murine recombinant products or a known allergy to murine products. A known allergy to murine product is definitely an exclusion criterion

- Documentation of seropositive for human immunodeficiency virus (HIV).

- A positive test for hepatitis B surface antigen or hepatitis C.

- Alcohol or substance abuse

- Known history of serious infections in the previous 3 months.

- Opportunistic infection within 6 months prior to screening.

- History of latent or active granulomatous infection.

- Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening.

- Chest radiograph within 3 months prior to randomization suggestive of malignancy or current active infection.

- Nontuberculous mycobacterial infection or opportunistic infection within 6 months prior to screening.

- History of lymphoproliferative disease.

- Any known malignancy or history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.

- Current signs or symptoms of severe, progressive or uncontrolled renal (other than disease under investigation), hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.

- Use of any investigational drug within 30 days prior to screening or within 5 half-lives of the investigational agent, whichever is longer.

- Previous treatment with drugs targeted at reducing TNF.

- Presence of a transplanted solid organ (with the exception of a corneal transplant > 3 months prior to screening).

- Concomitant diagnosis or history of congestive heart failure.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
infliximab
azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
placebo
azathioprine (2 mg/kg) plus four placebo infusions

Locations

Country Name City State
Austria Departments of Rheumatology, Internal Medicine, Medical University of Graz Graz
Austria Internal Medicine II, Hietzing Hospital Vienna
Austria Rheumatology, Internal Medicine III, Medical University of Vienna Vienna
Germany Rheumatology, Charite Berlin
Germany Rheumatology, University of Düsseldorf Düsseldorf
Germany Internal Medicine III, University of Erlangen Erlangen
Netherlands Clinical Immunology, Groningen University Hospital Groningen
Netherlands Leiden University Medical Center, Netherlands Leiden
Netherlands Nephrology, University of Nymegen, Netherlands Nijmegen

Sponsors (9)

Lead Sponsor Collaborator
Medical University of Vienna Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, Hospital Hietzing, Leiden University Medical Center, Medical University of Graz, Radboud University, University Medical Center Groningen, University of Erlangen-Nürnberg

Countries where clinical trial is conducted

Austria,  Germany,  Netherlands, 

References & Publications (1)

Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004 Oct;50(10):3161-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of time needed to reduce proteinuria to 1.5 g/day or less between the infliximab plus azathioprine and the azathioprine only group. No
Secondary Percentage of patients reaching reduction in proteinuria to = 1.5 g/day, at week 12 and week 52. No
Secondary Percent reduction in proteinuria at 6 weeks, 12 weeks, 20 weeks, 36 weeks, and 52 weeks after the first infusion. No
Secondary Absolute reduction in proteinuria at 6 weeks, 12 weeks, 20 weeks, 36 weeks, and 52 weeks after the first infusion. No
Secondary Percent reduction in protein/ creatinine ratio. No
Secondary Percent reduction in SLE disease activity (measured by SIS and SLEDAI). Yes
Secondary Absolute reduction in SLE disease activity (measured by SIS and SLEDAI). Yes
Secondary Changes in Quality of life as determined by the SF36 questionnaire. No
Secondary Changes in Fatigue as determined by the FSS (Fatigue Severity Scale). No
See also
  Status Clinical Trial Phase
Recruiting NCT02936375 - The Iguratimod Effect on Lupus Nephritis (IGeLU) Phase 2
Completed NCT03597464 - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin Phase 3
Recruiting NCT01226147 - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis Phase 2
Completed NCT01206569 - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Phase 4
Active, not recruiting NCT00569101 - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis Phase 2
Completed NCT00371319 - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Phase 4
Completed NCT00298506 - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) N/A
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Terminated NCT04376827 - A Study of Guselkumab in Participants With Active Lupus Nephritis Phase 2
Completed NCT03610516 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. Phase 2
Recruiting NCT03526042 - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis N/A
Withdrawn NCT03859570 - Pentoxifylline in Lupus Nephritis Phase 4
Completed NCT03664908 - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? N/A
Completed NCT01085097 - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Phase 2
Active, not recruiting NCT05704088 - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT06429800 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis Phase 1
Recruiting NCT02226341 - ACTHar in the Treatment of Lupus Nephritis Phase 4
Recruiting NCT02453997 - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis N/A
Completed NCT01470183 - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients N/A
Terminated NCT00089804 - Study of LJP 394 in Lupus Patients With History of Renal Disease Phase 3